跳至主要内容
临床试验/PER-051-01
PER-051-01未知未知

EFFECT OF A PLAQUETARY BLOCKER IIB / IIA (TIROFIBAN) IN TRANSLUMINAL PERIPHERAL ANGIOPLASTY

MERCK & CO.INC.,0 个研究点目标入组 0 人开始时间: 2001年8月3日最近更新:
适应症

试验速览

阶段
未知
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
0 至 0(—)

入选标准

  • All patients with a diagnosis of Fontain IIb peripheral obstructive arteriopathy, angiographic category 1, Aortoiliac and Iliofemoral sector, whose choice therapy following the international criteria applied in the institution, is the elective ATP, hospitalized in the 2BE of the HNGAI.

排除标准

  • Gestation or suspicion of it.
  • Contraindication of anticoagulation or increased risk of bleeding:
  • Recent active bleeding (<1 year): gastrointestinal hemorrhage, hematuria, renal lithiasis,
  • presence or suspicion of coagulopathy, platelet disorder or history of thrombocytopenia.
  • Systolic arterial hypertension> 180 mmHg and / or diastolic blood pressure> 110 Hg, at the time of entering the study.
  • History of hemorrhagic cerebrovascular disease or active intracranial pathological process (neoplasia, arteriovenous malformation or aneurysm). Any history of cerebrovascular disease in the last year (stroke or transient ischemic attack).
  • Trauma or prolonged cardiopulmonary resuscitation maneuvers in the last 2 weeks prior to the study.
  • Severe trauma in the last month prior to the study.
  • Major surgery, any ophthalmic surgery or biopsy in the month prior to the study.
  • Active ulceropeptic disease in the last 3 months prior to the study.
  • Acute pericarditis.
  • Presence of significant retinopathy (hemorrhagic or proliferative).
  • Thrombolytic therapy in the 48 hours prior to the study.
  • Treatment with Abciximab (ReoPro) or Eptifibatide (Integrilin) ​​14 days prior to the study.
  • Patients on chronic treatment with Ticlopidine or Clopidogrel, or who have received> = 500 mg of Ticlopidine or> 75 mg of Clopidogrel in the previous 48 hours.
  • Patients using Warfarin.
  • Patients under spinal / epidural anesthesia or spinal puncture (due to risk of epidural or spinal hematoma, which has caused neurological injury including: permanent / prolonged paralysis, or those receiving low molecular weight heparins).
  • Allergy or hypersensitivity to Tirofiban, Aspirin,
  • Heparin, low molecular weight heparin, or any component of these products.
  • Patients with severe cardiovascular disease who require urgent therapy
  • History or symptoms suggestive of aortic dissection (pain radiating to the back).
  • Patients with acute pulmonary edema (presence of rales in more than 50% of lung fields) or severe congestive heart failure (New York Heart Association, functional class III or IV).
  • Appearance of angina due to known precipitating factors (arrhythmia, infection, severe anemia, hyperthyroidism).
  • Patients with severe uncontrolled cardiac arrhythmia (leading to hemodynamic instability).
  • Systolic pressure <95mm Hg or cardiogenic shock at the time of study inclusion.
  • Presence of more than 50% of left cardiac injury not protected by bypass.
  • Patients with significant valvular disease, hypertrophic cardiomyopathy, restrictive cardiomyopathy, or congenital heart disease.
  • Patients with any medical condition, which, in the opinion of the investigators, presumes a survival incompatible with the duration of the study, interference with the participation in it or means a risk for the patient:
  • History of alcohol or other drug abuse.
  • Patients with a history of cancer except for basal cell carcinoma of the skin.
  • Patient with significant systemic failure: renal, hepatic, endocrine, neurological or hematologic.
  • Patient with important laboratory abnormalities

研究者

发起方
MERCK & CO.INC.,

相似试验